Withdrawal from repeated morphine sensitizes mice to the striatal dopamine release enhancing effect of acute morphine. 1994

J Airio, and M Attila, and T Leikola-Pelho, and L Ahtee
Department of Pharmacy, University of Helsinki, Finland.

The effects of morphine withdrawal and challenge on the alpha-methyl-rho-tyrosine (alpha MT)-induced depletion of dopamine (DA) as well as on DA metabolism and 3H-SCH 23390 and 3H-spiperone binding were studied in the striata of male mice. Morphine was given s.c. 3 times daily for 5 days followed by 1 to 3 days' withdrawal. The alpha MT-induced DA depletion was retarded in mice withdrawn for 1 day from repeated morphine. At this time point the striatal concentrations of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) fell, too. In mice withdrawn for 3 days from morphine neither DA depletion nor DOPAC or HVA concentrations differed from those of control mice. In control mice acute morphine challenge accelerated the DA depletion at the dose 10 mg/kg but not at the dose 30 mg/kg. Both doses elevated striatal DOPAC and HVA. In mice withdrawn from repeated morphine for 1 day acute morphine partially counteracted the withdrawal-induced retardation of DA depletion and elevated striatal DOPAC and HVA clearly less than in control mice. However, in mice withdrawn for 3 days 10 mg/kg of morphine clearly enhanced DA depletion and its effect on striatal HVA was significantly augmented. In these mice as in controls the 30 mg/kg dose did not alter striatal DA depletion and elevated HVA less than in controls. Acute morphine did not alter striatal 3-methoxytyramine (3-MT) concentration in control mice but at the dose 10 mg/kg increased it in mice withdrawn for 3 days.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008781 Methyltyrosines A group of compounds that are methyl derivatives of the amino acid TYROSINE.
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D006719 Homovanillic Acid A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid. 3-Methoxy-4-Hydroxyphenylacetic Acid,4-Hydroxy-3-Methoxyphenylacetic Acid,3 Methoxy 4 Hydroxyphenylacetic Acid,4 Hydroxy 3 Methoxyphenylacetic Acid,Acid, 3-Methoxy-4-Hydroxyphenylacetic,Acid, 4-Hydroxy-3-Methoxyphenylacetic,Acid, Homovanillic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001552 Benzazepines Compounds with BENZENE fused to AZEPINES.
D013134 Spiperone A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA. Spiroperidol,Spiroperone
D014793 Visual Cortex Area of the OCCIPITAL LOBE concerned with the processing of visual information relayed via VISUAL PATHWAYS. Area V2,Area V3,Area V4,Area V5,Associative Visual Cortex,Brodmann Area 18,Brodmann Area 19,Brodmann's Area 18,Brodmann's Area 19,Cortical Area V2,Cortical Area V3,Cortical Area V4,Cortical Area V5,Secondary Visual Cortex,Visual Cortex Secondary,Visual Cortex V2,Visual Cortex V3,Visual Cortex V3, V4, V5,Visual Cortex V4,Visual Cortex V5,Visual Cortex, Associative,Visual Motion Area,Extrastriate Cortex,Area 18, Brodmann,Area 18, Brodmann's,Area 19, Brodmann,Area 19, Brodmann's,Area V2, Cortical,Area V3, Cortical,Area V4, Cortical,Area V5, Cortical,Area, Visual Motion,Associative Visual Cortices,Brodmanns Area 18,Brodmanns Area 19,Cortex Secondary, Visual,Cortex V2, Visual,Cortex V3, Visual,Cortex, Associative Visual,Cortex, Extrastriate,Cortex, Secondary Visual,Cortex, Visual,Cortical Area V3s,Extrastriate Cortices,Secondary Visual Cortices,V3, Cortical Area,V3, Visual Cortex,V4, Area,V4, Cortical Area,V5, Area,V5, Cortical Area,V5, Visual Cortex,Visual Cortex Secondaries,Visual Cortex, Secondary,Visual Motion Areas

Related Publications

J Airio, and M Attila, and T Leikola-Pelho, and L Ahtee
March 1997, Neurochemical research,
J Airio, and M Attila, and T Leikola-Pelho, and L Ahtee
April 1993, European journal of pharmacology,
J Airio, and M Attila, and T Leikola-Pelho, and L Ahtee
August 1977, European journal of pharmacology,
J Airio, and M Attila, and T Leikola-Pelho, and L Ahtee
November 1990, European journal of pharmacology,
J Airio, and M Attila, and T Leikola-Pelho, and L Ahtee
January 2015, Psychopharmacology,
J Airio, and M Attila, and T Leikola-Pelho, and L Ahtee
March 2002, Psychopharmacology,
J Airio, and M Attila, and T Leikola-Pelho, and L Ahtee
December 1977, Journal of neurochemistry,
J Airio, and M Attila, and T Leikola-Pelho, and L Ahtee
January 1978, Annali dell'Istituto superiore di sanita,
J Airio, and M Attila, and T Leikola-Pelho, and L Ahtee
August 1993, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!